End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience.

MLA

Mahaffey, Kenneth W., et al. “End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience.” Circulation: Cardiovascular Quality & Outcomes, vol. 6, no. 4, July 2013, pp. 470–78. EBSCOhost, https://doi.org/10.1161/CIRCOUTCOMES.113.000132.

APA

Mahaffey, K. W., Hellkamp, A. S., Patel, M. R., Hannan, K. L., Schwabe, K., Nessel, C. C., Berkowitz, S. D., Halperin, J. L., Hankey, G. J., Becker, R. C., Piccini, J. P., Breithardt, G., Hacke, W., Singer, D. E., Califf, R. M., & Fox, K. A. A. (2013). End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience. Circulation: Cardiovascular Quality & Outcomes, 6(4), 470–478. https://doi.org/10.1161/CIRCOUTCOMES.113.000132

Chicago

Mahaffey, Kenneth W, Anne S Hellkamp, Manesh R Patel, Karen L Hannan, Kimberly Schwabe, Christopher C Nessel, Scott D Berkowitz, et al. 2013. “End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience.” Circulation: Cardiovascular Quality & Outcomes 6 (4): 470–78. doi:10.1161/CIRCOUTCOMES.113.000132.